Scrip
Wyeth and WHO launch Phase III trial for river blindness drug
03 July 2009
Asher Mullard
Please Login to read the full article.
03 July 2009
Asher Mullard
Wyeth Pharmaceuticals has launched Phase III trials in three African countries to test reformulated animal antiparasitic moxidectin as a treatment for river blindness, a disease caused by the parasite Onchocerca volvulus that results in loss of sight, rashes and skin lesions.
Moxidectin...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
- Amarin focused on CV disease to pump new life into company
- Anti-obesity drugs: an inventor's perspective
EVENTS
22 March 2010
London, UK
12 April 2010
Orlando, Florida
13 April 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
